Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Relay Therapeutics, Inc. (RLAY) vs Xenon Pharmaceuticals Inc. (XENE)

Relay Therapeutics, Inc. and Xenon Pharmaceuticals Inc. are both Biotechnology companies. Relay Therapeutics, Inc. and Xenon Pharmaceuticals Inc. are of similar size ($3.9B and $3.7B). Xenon Pharmaceuticals Inc. grew revenue faster over the last twelve months: −8.15% against −74.3%. Xenon Pharmaceuticals Inc. has the higher net margin (0.00% vs −2,594.2%) and the lower return on invested capital (−88.5% vs 0.00%). Across the 17 metrics below, Xenon Pharmaceuticals Inc. leads on 10 and Relay Therapeutics, Inc. on 7.

Valuation

Metric RLAY XENE Biotechnology median
P/E n/m n/m 7.88
P/S 323.06 217.29 11.47
P/B 4.00 2.96 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 240.44 162.98 10.73
Earnings yield (8.94%) (12.83%) (28.84%)
Free cash flow yield (5.97%) (9.20%) (23.03%)

Profitability

Metric RLAY XENE Biotechnology median
Gross margin 100.00% 28.40% 65.16%
Operating margin (2,815.49%) 0.00% 0.00%
Net margin (2,594.20%) 0.00% 0.00%
Free cash flow margin (1,924.59%) 0.00% 0.00%
Return on equity (36.77%) (43.62%) (57.72%)
Return on assets (33.72%) (41.54%) (49.22%)
Return on invested capital 0.00% (88.54%) 0.00%

Growth

Metric RLAY XENE Biotechnology median
Revenue growth (TTM) (74.29%) (8.15%) 5.64%
EPS growth (last fiscal year) 31.78% (44.85%) —
Revenue growth, 5-year CAGR (28.58%) 89.00% 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric RLAY XENE Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 18.27 21.02 4.73
Net debt to EBITDA 1.84 1.48 0.96

Dividend

Metric RLAY XENE Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric RLAY XENE Biotechnology median
Market cap 3.91b 3.73b 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack